Abstract
Purpose
To examine the prevalence and risk factors for hypercalcemia among non-dialysis chronic kidney disease (CKD) patients with mineral and bone disorder (MBD).
Methods
A retrospective cohort study was conducted in Singapore General Hospital, involving all CKD stage 4 and 5 pre-dialysis patients who were on treatment for MBD in June 2016. Each patient was followed up for 1 year and screened for hypercalcemia episodes. Mild, moderate and severe hypercalcemia were defined as corrected calcium of 2.47–3.00, 3.01–3.50 and ≥ 3.51 mmol/l respectively. Patients who were on dialysis, post-renal transplant, post-parathyroidectomy or had no calcium levels taken during the study period were excluded. Details related to patients’ clinical information and hypercalcemia episodes were collected. Multivariate logistic regression analysis was performed to evaluate risk factors for hypercalcemia.
Results
Of 557 patients, 75 (13.4%) patients developed hypercalcemia. There were 120 (97.6%) mild and 3 (2.4%) moderate hypercalcemia episodes. The daily elemental calcium intake from phosphate binders and usage of vitamin D analogues did not differ between patients with and without hypercalcemia (p > 0.05). After adjusting for covariates, lower baseline iPTH level [odds ratio (OR) 0.96, 95% CI 0.93–0.99], history of hypercalcemia in past 1 year (OR 11.11, 95% CI 3.36–36.75) and immobility (OR 3.34, 95% CI 1.34–8.40) were associated with increased hypercalcemia risk.
Conclusion
Hypercalcemia affects a significant proportion of pre-dialysis patients with MBD. More studies should be undertaken to evaluate other risk factors associated with hypercalcemia.
Similar content being viewed by others
References
Jha V, Garcia-Garcia G, Iseki K, Li Z, Naicker S, Plattner B, Saran R, Wang AY, Yang CW (2013) Chronic kidney disease: global dimension and perspectives. Lancet 382(9888):260–272. https://doi.org/10.1016/s0140-6736(13)60687-x
Wee H-L, Seng BJJ, Lee JJ, Chong KJ, Tyagi P, Vathsala A, How P (2016) Association of anemia and mineral and bone disorder with health-related quality of life in Asian pre-dialysis patients. Health Qual Life Outcomes 14:94. https://doi.org/10.1186/s12955-016-0477-8
Slinin Y, Foley RN, Collins AJ (2005) Calcium, phosphorus, parathyroid hormone, and cardiovascular disease in hemodialysis patients: the USRDS waves 1, 3, and 4 study. J Am Soc Nephrol 16(6):1788–1793. https://doi.org/10.1681/asn.2004040275
Rivara MB, Ravel V, Kalantar-Zadeh K, Streja E, Lau WL, Nissenson AR, Kestenbaum B, de Boer IH, Himmelfarb J, Mehrotra R (2015) Uncorrected and albumin-corrected calcium, phosphorus, and mortality in patients undergoing maintenance dialysis. J Am Soc Nephrol 26(7):1671–1681. https://doi.org/10.1681/asn.2014050472
Kovesdy CP, Kuchmak O, Lu JL, Kalantar-Zadeh K (2010) Outcomes associated with serum calcium level in men with non-dialysis-dependent chronic kidney disease. Clin J Am Soc Nephrol 5(3):468–476. https://doi.org/10.2215/CJN.06040809
Meric F, Yap P, Bia MJ (1990) Etiology of hypercalcemia in hemodialysis patients on calcium carbonate therapy. Am J Kidney Dis 16(5):459–464
Bleyer AJ, Burke SK, Dillon M, Garrett B, Kant KS, Lynch D, Rahman SN, Schoenfeld P, Teitelbaum I, Zeig S, Slatopolsky E (1999) A comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients. Am J Kidney Dis 33(4):694–701
Moe S, Drueke T, Cunningham J, Goodman W, Martin K, Olgaard K, Ott S, Sprague S, Lameire N, Eknoyan G (2006) Definition, evaluation, and classification of renal osteodystrophy: a position statement from kidney disease: improving global outcomes (KDIGO). Kidney Int 69(11):1945–1953. https://doi.org/10.1038/sj.ki.5000414
WHO Expert Consultation (2004) Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet 363(9403):157–163. https://doi.org/10.1016/s0140-6736(03)15268-3
Pai M, Lloyd NS, Cheng J, Thabane L, Spencer FA, Cook DJ, Haynes RB, Schunemann HJ, Douketis JD (2013) Strategies to enhance venous thromboprophylaxis in hospitalized medical patients (SENTRY): a pilot cluster randomized trial. Implement Sci 8:1. https://doi.org/10.1186/1748-5908-8-1
Payne RB, Little AJ, Williams RB, Milner JR (1973) Interpretation of serum calcium in patients with abnormal serum proteins. BMJ 4(5893):643–646
Carroll MF, Schade DS (2003) A practical approach to hypercalcemia. Am Fam Physician 67(9):1959–1966
Kong X, Zhang L, Zhang L, Chen N, Gu Y, Yu X, Liu W, Chen J, Peng L, Yuan W, Wu H, Chen W, Fan M, He L, Ding F, Chen X, Xiong Z, Zhang J, Jia Q, Shi W, Xing C, Tang X, Hou F, Shu G, Mei C, Wang L, Xu D, Ni Z, Zuo L, Wang M, Wang H (2012) Mineral and bone disorder in Chinese dialysis patients: a multicenter study. BMC Nephrol 13:116. https://doi.org/10.1186/1471-2369-13-116
Vikrant S, Parashar A (2016) Prevalence and severity of disordered mineral metabolism in patients with chronic kidney disease: a study from a tertiary care hospital in India. Indian J Endocrinol Metab 20(4):460–467. https://doi.org/10.4103/2230-8210.183457
Cheng CJ, Chou CH, Lin SH (2006) An unrecognized cause of recurrent hypercalcemia: immobilization. South Med J 99(4):371–374. https://doi.org/10.1097/01.smj.0000210142.76331.b4
Teo HK, Wong J (2017) Unusual cause of hypercalcaemia in end stage renal failure patients. Hemodial Int 21(2):E40–E44. https://doi.org/10.1111/hdi.12512
Spatz JM, Wein MN, Gooi JH, Qu Y, Garr JL, Liu S, Barry KJ, Uda Y, Lai F, Dedic C, Balcells-Camps M, Kronenberg HM, Babij P, Pajevic PD (2015) The Wnt inhibitor sclerostin is up-regulated by mechanical unloading in osteocytes in vitro. J Biol Chem 290(27):16744–16758. https://doi.org/10.1074/jbc.M114.628313
Palmer SC, McGregor DO, Macaskill P, Craig JC, Elder GJ, Strippoli GF (2007) Meta-analysis: vitamin D compounds in chronic kidney disease. Ann Intern Med 147(12):840–853
Thadhani R, Appelbaum E, Pritchett Y, Chang Y, Wenger J, Tamez H, Bhan I, Agarwal R, Zoccali C, Wanner C, Lloyd-Jones D, Cannata J, Thompson BT, Andress D, Zhang W, Packham D, Singh B, Zehnder D, Shah A, Pachika A, Manning WJ, Solomon SD (2012) Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial. Jama 307(7):674–684. https://doi.org/10.1001/jama.2012.120
Wang AY, Fang F, Chan J, Wen YY, Qing S, Chan IH, Lo G, Lai KN, Lo WK, Lam CW, Yu CM (2014) Effect of paricalcitol on left ventricular mass and function in CKD—the OPERA trial. J Am Soc Nephrol 25(1):175–186. https://doi.org/10.1681/asn.2013010103
Wilson RJ, Copley JB (2017) Elemental calcium intake associated with calcium acetate/calcium carbonate in the treatment of hyperphosphatemia. Drugs Context 6:212302. https://doi.org/10.7573/dic.212302
Ghimire S, Castelino RL, Lioufas NM, Peterson GM, Zaidi STR (2015) Nonadherence to medication therapy in haemodialysis patients: a systematic review. PLoS ONE 10(12):e0144119. https://doi.org/10.1371/journal.pone.0144119
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Seng, J.J.B., Tan, Y.L.C., Lim, R.W. et al. Prevalence and risk factors for hypercalcemia among non-dialysis patients with chronic kidney disease-mineral and bone disorder. Int Urol Nephrol 50, 1871–1877 (2018). https://doi.org/10.1007/s11255-018-1906-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11255-018-1906-x